肠道微生物群和代谢物在癌症化疗中的作用。
The role of gut microbiota and metabolites in cancer chemotherapy.
机构信息
Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen research Institute, The Chinese University of Hong Kong, Hong Kong, China.
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
J Adv Res. 2024 Oct;64:223-235. doi: 10.1016/j.jare.2023.11.027. Epub 2023 Nov 26.
BACKGROUND
The microbiota inhabits the epithelial surfaces of hosts, which influences physiological functions from helping digest food and acquiring nutrition to regulate metabolism and shaping host immunity. With the deep insight into the microbiota, an increasing amount of research reveals that it is also involved in the initiation and progression of cancer. Intriguingly, gut microbiota can mediate the biotransformation of drugs, thereby altering their bioavailability, bioactivity, or toxicity.
AIM OF REVIEW
The review aims to elaborate on the role of gut microbiota and microbial metabolites in the efficacy and adverse effects of chemotherapeutics. Furthermore, we discuss the clinical potential of various ways to harness gut microbiota for cancer chemotherapy.
KEY SCIENTIFIC CONCEPTS OF REVIEW
Recent evidence shows that gut microbiota modulates the efficacy and toxicity of chemotherapy agents, leading to diverse host responses to chemotherapy. Thereinto, targeting the microbiota to improve efficacy and diminish the toxicity of chemotherapeutic drugs may be a promising strategy in tumor treatment.
背景
微生物群栖息在宿主的上皮表面，从帮助消化食物和获取营养到调节代谢和塑造宿主免疫，影响着生理功能。随着对微生物群的深入了解，越来越多的研究表明，它也参与了癌症的发生和发展。有趣的是，肠道微生物群可以介导药物的生物转化，从而改变其生物利用度、生物活性或毒性。
综述目的
本文旨在阐述肠道微生物群和微生物代谢物在化疗药物疗效和不良反应中的作用。此外，我们还讨论了利用肠道微生物群进行癌症化疗的各种方法的临床潜力。
综述的关键科学概念
最近的证据表明，肠道微生物群调节化疗药物的疗效和毒性，导致宿主对化疗的反应不同。其中，靶向微生物群以提高化疗药物的疗效和降低其毒性可能是肿瘤治疗的一种有前途的策略。
Zotero 插件